Background French national health care insurance system database has suggested 1–3
years use of glucagon like peptide-1 receptor agonists (GLP1RA)(exenatide, liraglutide and …

Background and aims To assess the safety and efficacy of semaglutide compared with
placebo and other anti-hyperglycaemic agents in type 2 diabetes (T2DM). Methods We …

Background Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist
used to treat patients with type 2 diabetes mellitus (T2DM). The SUSTAIN 6 trial found a …

Aims Obesity is a major risk factor for atrial fibrillation (AF). Compared with stable weight,
gaining weight was associated with a higher risk of incident AF in observational studies. The …

Several studies have found that antifibrosis treatment for nonalcoholic fatty liver disease
(NAFLD) can cause a variety of side effects. No network meta-analysis (NMA) analyzes the …

Ischemia with nonobstructive coronary artery disease (INOCA) is increasingly recognized as
a significant cause of angina, myocardial remodeling, and eventually heart failure (HF) …

Aim Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide 1
receptor agonists (GLP-1RAs) are two new classes of antidiabetic agents. We aimed to …

What is known and objective New hypoglycaemic agents consist of dipeptidyl peptidase four
inhibitors (DPP4is), glucagon‐like peptide one receptor agonists (GLP1RAs) and sodium …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular
benefits in type 2 diabetes, but none of the cardiovascular trials studied atrial fibrillation/atrial …

Semaglutide has little hepatic metabolism and is deemed low risk for causing drug-induced
liver injury (DILI). We present a case of DILI from the US DILI Network. The case involved a …